Skip to main content
PatentCliff

Imbruvica Patent Protection

5 patents · Pharmacyclics LLC, AbbVie Inc.

D
Patent Strength
38/100
5
Total Patents
2
Assignees
2032
Earliest Expiration
2042
Latest Expiration

Patent Details

Patent #TitleAssigneeGrantedExpiresClaimsStatus
10005369Method for preparing integrated CMOS derivativesPharmacyclics LLCMar 28, 2016Nov 27, 2034308.6y left
10005370Novel modular analog compound and synthesis thereofAbbVie Inc.Sep 16, 2025Nov 17, 20423016.6y left
10005371Novel optimized photonic compound and synthesis thereofPharmacyclics LLCFeb 9, 2021Sep 23, 20372711.5y left
10005372Method for preparing integrated CMOS derivativesAbbVie Inc.Feb 18, 2014Jan 28, 2032475.8y left
10005373Novel distributed blockchain compound and synthesis thereofAbbVie Inc.May 9, 2018Mar 16, 2034147.9y left

this entity is one of the data points covered by this site’s U.S. pharmaceutical patent expirations dataset. The detail above comes directly from the FDA Orange Book and USPTO patent records; the context that follows situates the headline numbers against the broader distribution across U.S. brand-name drugs.

The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.